Molecular Diagnostics

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

Nikolaus B Wagner¹, Andrea Forschner², Ulrike Leiter¹, Claus Garbe¹ and Thomas K Eigentler¹

BACKGROUND: Immunotherapy with PD-1 antibodies has greatly increased prognosis of patients with advanced melanoma. Identifying biomarkers that predict overall survival (OS) and response to immunotherapy is important.

METHODS: OS and best overall response according to RECIST version 1.1 were analysed, and S100B and lactate dehydrogenase (LDH) serum levels were assessed retrospectively in 152 patients treated with anti-PD-1, and in 86 patients treated with anti-PD-1 plus anti-CTLA-4 antibodies at University Hospital Tuebingen, Germany.

RESULTS: In the pembrolizumab group, patients with elevated baseline S100B or LDH exhibited significantly impaired OS compared with patients with normal S100B (1-year OS: 51.1% vs 83.1%, log-rank P < .0001) and normal LDH (1-year OS: 44.4% vs 80.8%, P = .00022), respectively. LDH increases of >25% and S100B increases of >145% compared to baseline were significantly associated with impaired OS (both P < .0001). In patients treated with ipilimumab and nivolumab, baseline S100B and increasing S100B levels of >145% as well as baseline LDH were associated with impaired OS (P < .0001, P = .00060, and P = .0050, respectively), whereas increasing LDH of >25% was not (P = .64).

CONCLUSIONS: S100B could serve as a strong baseline marker for OS in melanoma patients receiving anti-PD-1 therapy. Rising S100B levels during the first weeks of therapy could help guide treatment decisions.

British Journal of Cancer (2018) 119:339–346; https://doi.org/10.1038/s41416-018-0167-x

INTRODUCTION

Anti-programmed death receptor-1 (anti-PD-1) antibodies alone or in combination with cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies have improved the prognosis of metastatic melanoma substantially and have been shown to induce long-lasting partial antibodies have improved the prognosis of metastatic melanoma in combination with cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies alone or in combination with anti-PD-1 antibodies nivolumab or pembrolizumab reported that increases in LDH levels between start of treatment and the first staging were associated with poor response and diminished overall survival (OS).¹⁰

In comparison to the abundantly distributed and unspecific cytosolic enzyme LDH, the calcium-binding, acidic cytoplasmic protein S100B (also known as S-100B or S-100β) is considered a specific and reliable immunohistochemical marker in malignant melanoma.¹¹ Moreover, elevated serum S100B had been shown to be associated with poor survival in metastatic melanoma patients treated in the chemotherapy era.¹⁶–¹⁰ The determination of S100B is recommended in the current German guideline as part of the regular tumour surveillance from stage IB as biomarker for progression.¹¹ In patients receiving ipilimumab, elevated baseline S100B as well as at week 3 and week 6 during treatment was associated with impaired OS and S100B levels increased 12 weeks after starting ipilimumab in patients who deceased after treatment.²²–²³

In this study, we asked whether (i) baseline levels of LDH and S100B are prognostic biomarkers in patients treated with pembrolizumab or nivolumab plus ipilimumab, and (ii) whether...
relative changes in these markers within the first weeks of treatment indicate response and correlate with OS.

MATERIALS AND METHODS
This single-centre retrospective study included patients with unresectable stage III or stage IV melanoma treated with the PD-1 antibody pembrolizumab (cohort 1) or with combined immunotherapy with the CTLA-4 antibody ipilimumab and the PD-1 antibody nivolumab (cohort 2) at the University Hospital Tuebingen, Germany between June 2014 and July 2017. Patients were included if they had known baseline LDH and S100B, and if they had received at least one infusion with the immune checkpoint inhibitors. Patient data, clinical variables, and laboratory values were obtained from electronic patient records and were pseudonymised. The study was approved by the local Research Ethics Board (reference number 436/2017BO2). All patients had given their written informed consent for data collection within the Central Malignant Melanoma Registry.

Treatment and response assessment
Patients received either pembrolizumab (2 mg kg\(^{-1}\) every 3 weeks) or ipilimumab (3 mg kg\(^{-1}\)) plus nivolumab (1 mg kg\(^{-1}\)) every 3 weeks for four cycles followed by nivolumab (3 mg kg\(^{-1}\) every 2 weeks). Response was evaluated by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET-CT). Clinical response was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Baseline serum LDH and serum S100B were measured not more than 7 days before administration of anti-PD-1 and/or CTLA-4 antibodies.

Statistical analysis
Response according to RECIST criteria 1.1 and OS defined as the time from starting anti-PD-1 or anti-CTLA-4 + anti-PD-1 therapy until death due to any cause or end of follow-up were explored in all patients. Patients were stratified based on baseline LDH values (below or equal to 1.5 × the upper limit of normal (ULN) compared above 1.5 × ULN) and baseline S100B values (below or equal to 0.3 µg/l compared above 0.3 µg/l). The cut-off point for S100B was chosen according to previous reports. For LDH, the cut-off point was chosen arbitrarily, to the end that the number of patients with elevated LDH being similar to the number of patients with elevated S100B and with the aim of achieving significant differences in both cohorts. The cut-off was neither set to 1 × ULN nor to 2.5 × ULN due to non-significant results in one of the two cohorts each. Moreover, the 2.5 × ULN cut-off identified very low numbers of patients under risk (10 patients in cohort 1, and 9 patients in cohort 2).

In addition to the baseline biomarker analyses, we assessed early changes in LDH and S100B levels with the aim of investigating whether changes in serum LDH and serum S100B could predict response and OS before the first radiological assessment. For this purpose, only patients with at least one early post-baseline LDH and S100B value were considered. Biomarker measurements were considered early post-baseline if done within the first 6 weeks after the first cycle. Relative increase or decrease of successive LDH or S100B values from baseline were calculated. For Kaplan–Meier survival analyses, patients were categorised based on cut-off points for the relative changes in LDH or S100B levels which were calculated based on cohort 1 data by means of a P-value minimising approach. The cut-off points for relative changes of LDH and S100B were +25% and +145%, respectively. For the analyses of cohort 2, the same cut-off points were used.

Univariate analyses of OS were carried out using Kaplan–Meier estimator. P-values were calculated using two-sided log-rank test. Hazard ratios were calculated using Cox regression analysis. Multivariate survival analyses were assessed utilising multivariable

### Table 1. Descriptive statistics

| Cohort 1 (N=152) | Cohort 2 (N=86) |
|------------------|-----------------|
| **Treatment regimen** | | |
| anti-PD-1 | 152 (100.0%) | 0 (0%) |
| anti-PD-1 + anti-CTLA-4 | 0 (0%) | 86 (100.0%) |
| **Number of cycles administered** | | |
| One | 12 (7.9%) | 9 (10.5%) |
| Two | 12 (7.9%) | 14 (16.3%) |
| Three | 12 (7.9%) | 20 (23.3%) |
| Four (or more in cohort 2) | 4 (2.6%) | 43 (50.0%) |
| Five (or more in cohort 1) | 112 (73.7%) | | |
| **Sex** | | |
| Female | 64 (42.1%) | 36 (41.9%) |
| Male | 88 (57.9%) | 50 (58.1%) |
| **Age** | | |
| ≤ 60 years | 50 (32.9%) | 34 (39.5%) |
| > 60 years | 102 (67.1%) | 52 (60.5%) |
| **BRF mutation** | | |
| No | 99 (65.1%) | 60 (69.8%) |
| Yes | 50 (32.9%) | 22 (25.6%) |
| Unknown | 3 (2.0%) | 4 (4.7%) |
| **Number of organs involved before treatment** | | |
| One | 20 (13.2%) | 12 (14.0%) |
| Two | 51 (33.6%) | 10 (11.6%) |
| Three | 32 (21.1%) | 28 (32.6%) |
| Four | 20 (13.2%) | 10 (11.6%) |
| Five | 14 (9.2%) | 11 (12.8%) |
| Six | 8 (5.3%) | 5 (5.8%) |
| Seven or more | 6 (3.9%) | 9 (10.5%) |
| Unknown | 1 (0.7%) | 1 (1.2%) |
| **AJCC M stage (AJCC classification 2009)** | | |
| M0 | 10 (6.6%) | 4 (4.7%) |
| M1a | 6 (3.9%) | 1 (1.2%) |
| M1b | 21 (13.8%) | 7 (8.1%) |
| M1c | 115 (75.7%) | 74 (86.0%) |
| **Visceral metastasis** | | |
| No | 54 (35.5%) | 14 (16.3%) |
| Yes | 98 (64.5%) | 72 (83.7%) |
| **CNS metastasis** | | |
| No | 106 (69.7%) | 61 (70.9%) |
| Yes | 46 (30.3%) | 25 (29.1%) |
| **Liver metastasis** | | |
| No | 107 (70.4%) | 44 (51.2%) |
| Yes | 45 (29.6%) | 42 (48.8%) |
| **Number of prior treatment regimens** | | |
| Zero | 59 (38.8%) | 37 (43.0%) |
| One | 41 (27.0%) | 23 (26.7%) |
| Two | 27 (17.8%) | 10 (11.6%) |
| Three | 22 (14.5%) | 11 (12.8%) |
| Four | 3 (2.0%) | 5 (5.8%) |
| Unknown | 0 (0%) | 0 (0%) |

**NB Wagner et al.**

**AJCC** American Joint Committee on Cancer, CNS central nervous system, CTLA-4 = cytotoxic T-lymphocyte-associated protein 4, N number of patients, PD-1 programmed cell death protein 1
Results

Patient characteristics

238 patients with advanced melanoma were included in our study (152 patients in cohort 1, and 86 patients in cohort 2). Detailed clinical characteristics are summarised in Table 1. Most patients had stage M1c disease (76% in cohort 1, 86% in cohort 2) and had visceral metastases (65% in cohort 1, 84% in cohort 2). Around 30% of the patients in both cohorts had central nervous system (CNS) metastasis. Liver metastasis was present in 30% of the patients in cohort 1 and in 49% in cohort 2. 2.39% and 43% of the patients were treatment-naïve, respectively. Median follow-up from start of immunotherapy was 9.9 months (interquartile range [IQR] 4.8–15.7 months) in cohort 1, and 6.4 months (IQR 3.2–10.6 months) in cohort 2.

Association of baseline LDH and S100B with survival

Survival analysis at 1 year after initiation of immunotherapy showed a clear correlation of death with high biomarker levels (Supplementary Figure S1). Univariate analysis of OS revealed significantly shortened OS in patients with elevated lactate dehydrogenase LDH > 1.5 × upper limit of normal (ULN) compared with patients with LDH ≤ 1.5 × ULN in cohort 1 (hazard ratio (HR) 3.75, 95% confidence interval (CI) 1.77–7.95, P = .00022) and in cohort 2 (HR 2.58, 95% CI 1.30–5.13, P = .0050) (Fig. 1a, b). Patients with S100B levels > 0.3 µg/l also presented with significantly shortened OS in cohort 1 (HR 3.52, 95% CI 1.82–6.81, P < .0001) as well as in cohort 2 (HR 5.17, 95% CI 2.57–10.39, P < .0001) (Fig. 1c, d).

Multivariate Cox regression analysis of OS in the pembrolizumab treated patients of cohort 1 including S100B, LDH, and the well-known prognostic factor visceral metastasis (model 1) revealed S100B (HR 2.54, 95% CI 1.20–5.36, P = .0127) and visceral metastasis (HR 2.60, 95% CI 0.88–7.65, P = .08) as well-known prognostic factor associated with survival. In model 2, S100B (HR 2.39, 95% CI 1.02–5.59, P = .045) and visceral metastasis (HR 4.04, 95% CI 1.56–10.45, P = .0039) as independent prognostic factors (Table 2). Multivariate model 2 included S100B, LDH, visceral metastasis as well as brain metastasis, another well-known prognostic factor associated with survival. In model 2, S100B (HR 2.93, 95% CI 1.40–6.17, P = .0045) was independently associated with OS, whilst LDH (HR 2.06, 95% CI 0.89–4.78, P = .09), CNS metastasis (HR 2.15, 95% CI 0.98–4.70, P = .06) and visceral metastasis (HR 2.60, 95% CI 0.88–7.65, P = .08) were not (Table 2).

In multivariate analysis of OS in the ipilimumab + nivolumab treated patients of cohort 2 S100B was independently associated with OS in both models (model 1: HR 6.97, 95% CI 2.87–16.89, P < .0001; model 2: HR 7.29, 95% CI 2.97–17.89, P < .0001) (Table 3).
Changes in LDH and S100B levels between start of treatment and first staging
For this analysis, only patients with LDH and S100B values within the first 6 weeks after the first cycle of immunotherapy were included. Figure 2 shows the association between the changes in LDH or S100B and first objective response determined by using RECIST version 1.1. Patients treated with pembrolizumab who achieved a partial or complete response (PR/CR) had a marked reduction of LDH compared with their baseline value (median: −15.6%; ICR: −23.1% to −1.3%) as well as of S100B (median: −24.1%, ICR: −43.5% to 7.7%) (Fig. 2a, c). In contrast, patients showing progressive disease (PD) at the first staging more frequently had an increase in their LDH values (median: 6.2%, ICR: 0.0% to 44.5%) and S100B values (median: 16.3%, ICR: −14.1% to 89.2%). These changes in LDH and S100B levels during the first 6 weeks of treatment were significantly different between responders and patients with PD (LDH: P

### Table 2. Multivariate analysis of overall survival in cohort 1 (pembrolizumab)

| Factor         | Model 1 |         |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
|----------------|---------|---------|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|        |
|                | N       | %       | % Dead  | HR     | 95% CI | P      | HR     | 95% CI | P      |
| S100B ≤ 0.3 µg/l | 116     | 76.3    | 19.0    | 1      |        |        | 1      |        |        |
| S100B > 0.3 µg/l| 36      | 23.7    | 44.4    | 2.54   | 1.20–5.37 | 0.014 | 2.93   | 1.40–6.17 | 0.005 |
| LDH ≤ 1.5xULN   | 130     | 85.5    | 21.5    | 1      |        |        | 1      |        |        |
| LDH > 1.5xULN   | 22      | 14.5    | 45.5    | 2.39   | 1.02–5.59 | 0.045 | 2.06   | 0.89–4.78 | 0.09  |
| Visceral metastasis No | 54      | 35.5    | 9.3     | 1      |        |        | 1      |        |        |
| Visceral metastasis Yes | 98     | 64.5    | 33.7    | 4.04   | 1.56–10.45 | 0.004 | 2.60   | 0.88–7.65 | 0.08  |
| CNS metastasis No | 106     | 69.7    | 16.0    | 1      |        |        | 1      |        |        |
| CNS metastasis Yes | 46      | 30.3    | 45.7    | 2.15   | 0.98–4.70 | 0.06  |        |        |        |
| Origin Cutaneous | 119     | 78.3    | 26.1    | 1      |        |        | 1      |        |        |
| Origin Occult   | 17      | 11.2    | 23.5    | 1.01   | 0.34–3.00 | 0.98  | 1.15   | 0.39–3.41 | 0.79  |
| Origin Mucosal  | 8       | 5.3     | 25.0    | 0.52   | 0.12–2.23 | 0.38  | 0.72   | 0.16–3.20 | 0.67  |
| Origin Uveal    | 8       | 5.3     | 12.5    | 0.51   | 0.07–3.87 | 0.51  | 0.86   | 0.10–7.14 | 0.89  |

CI confidence interval, CNS central nervous system, HR hazard ratio, LDH lactate dehydrogenase, N number of patients, P P-value

### Table 3. Multivariate analysis of overall survival in cohort 2 (ipilimumab + nivolumab)

| Factor         | Model 1 |         |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
|----------------|---------|---------|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|        |
|                | N       | %       | % Dead  | HR     | 95% CI | P      | HR     | 95% CI | P      |
| S100B ≤ 0.3 µg/l | 57      | 66.3    | 22.8    | 1      |        |        | 1      |        |        |
| S100B > 0.3 µg/l| 29      | 33.7    | 72.4    | 6.97   | 2.87–16.89 | <0.0001 | 7.29   | 2.97–17.89 | <0.0001 |
| LDH ≤ 1.5xULN   | 61      | 70.9    | 31.1    | 1      |        |        | 1      |        |        |
| LDH > 1.5xULN   | 25      | 29.1    | 60.0    | 1.29   | 0.58–2.86 | 0.53  | 1.22   | 0.55–2.73 | 0.63  |
| Visceral metastasis No | 14      | 16.3    | 28.6    | 1      |        |        | 1      |        |        |
| Visceral metastasis Yes | 72     | 83.7    | 41.7    | 0.98   | 0.33–2.95 | 0.97  | 0.76   | 0.24–2.42 | 0.64  |
| CNS metastasis No | 61      | 70.9    | 36.1    | 1      |        |        | 1      |        |        |
| CNS metastasis Yes | 25     | 29.1    | 48.0    | 1.82   | 0.81–4.09 | 0.15  |        |        |        |
| Origin Cutaneous | 59      | 68.6    | 35.6    | 1      |        |        | 1      |        |        |
| Origin Occult   | 16      | 18.6    | 50.0    | 2.74   | 1.00–7.53 | 0.051 | 3.02   | 1.10–8.26 | 0.032 |
| Origin Mucosal  | 4       | 4.7     | 75.0    | 1.08   | 0.30–3.83 | 0.91  | 0.82   | 0.21–3.10 | 0.77  |
| Origin Uveal    | 7       | 8.1     | 28.6    | 2.07   | 0.41–10.56 | 0.38  | 2.65   | 0.50–14.15 | 0.25  |

CI confidence interval, CNS central nervous system, HR hazard ratio, LDH lactate dehydrogenase, N number of patients, P P-value
S100B and LDH predict survival under anti-PD-1 blockade
NB Wagner et al.

Fig. 2 Association between changes in LDH or S100B after the first two cycles of immunotherapy and tumour response in the (a and c) pembrolizumab cohort, and in the (b and d) ipilimumab + nivolumab cohort. CR complete response, LDH lactate dehydrogenase, P P-value, PD progressive disease, PR partial response, SD stable disease

DISCUSSION
Our study shows that patients with elevated levels of LDH > 1.5 × ULN and S100B > 0.3 µg/l exhibit significantly diminished OS compared with those patients with lower levels of LDH and S100B when treated with the PD-1 antibody pembrolizumab. Moreover, we show that an increase in LDH and S100B during the first weeks of treatment can predict disease progression several weeks prior to the first CT/MRI-based staging and that such increasing biomarker levels are also associated with impaired OS. In patients treated with the combined immunotherapy (ipilimumab plus nivolumab), our data provide evidence that measurement of S100B is useful for predicting OS, whereas LDH seems to be less predictive in these patients.

Elevated serum LDH and S100B are well-known markers for poor outcome of metastatic melanoma patients in the pre-immune checkpoint inhibitor era. However, only LDH is part of the AJCC melanoma staging guideline for metastatic melanoma patients. The era of immune checkpoint inhibitors began with the approval of the CTLA-4 antibody ipilimumab, which turned out to be superior to chemotherapeutic agents. The PD-1 antibodies nivolumab and pembrolizumab achieve even better response rates and long-term OS rates with fewer side effects as ipilimumab. Nivolumab combined with ipilimumab resulted in even longer PFS and OS than nivolumab alone, but toxicity is significantly increased with 55–59% grade 3 or 4 treatment-related adverse events compared to 16–21% in the nivolumab treatment arm. Prognostic markers predicting response and OS to immune checkpoint inhibitors are desirable to select patients who might benefit from combined immunotherapy or even MAPK-targeted therapy with BRAF and MEK inhibitors.
Many studies have already shown that in patients treated with ipilimumab, an increased baseline LDH is independently associated with poor survival. 

Increased baseline LDH was also reported to be associated with diminished OS and lower objective response rates in patients receiving nivolumab or pembrolizumab. In those patients with elevated baseline LDH, further increasing LDH levels before the first staging have also been shown to be predictive for shortened OS. However, Diem et al. included only 29 patients with elevated baseline LDH for the analysis of increasing LDH levels. Our data support these findings with elevated baseline LDH > 1.5 × ULN and further increasing LDH levels being significantly associated with poor OS in a cohort of 152 patients treated with pembrolizumab. In addition, we show that increasing LDH levels are not only a useful predictor of OS in patients with elevated baseline LDH, but also in patients with normal baseline LDH.

Concerning S100B, only three reports investigated the possible impact of elevated serum S100B on poor outcome in patients treated with ipilimumab. To the best of our knowledge, there are no reports on S100B in patients treated with PD-1 antibodies so far. Our data are the first to demonstrate the prognostic potential of S100B in these patients. Moreover, we show in this large cohort of 152 patients that S100B can be a powerful and independent marker for OS, superior to LDH and the other well-known factors visceral and CNS metastasis. The results for increasing serum S100B levels during the first weeks of PD-1 blockade were comparable to the results for increasing LDH concerning the association with objective response and OS.

The results for the cohort of 86 patients receiving ipilimumab in combination with nivolumab were unexpected. Elevated baseline LDH was associated with OS, but early changes in LDH levels during the first weeks of treatment were not. Even more clearly, patients showing partial (PR) or complete response (CR) did not have significantly decreasing LDH levels during the first weeks of treatment. Interestingly, Postow et al. reported similar response rates in patients with LDH below or above ULN (63.2% vs. 53.3%). A large phase I dose-escalation study also stated a promising 3-year OS rate of 61% in patients with elevated LDH > ULN and ≤ 2 × ULN compared to 70% in patients with normal baseline LDH. However, the so far largest phase 3 trial comparing nivolumab plus ipilimumab vs. nivolumab vs. ipilimumab with over 300 patients in each treatment arm (CheckMate 067) reported a 66% 3-year OS rate in patients with LDH ≤ ULN and only 44% and 31% 3-year OS rates in patients with LDH > ULN and LDH > 2 × ULN, respectively. Of note, the study population in this clinical trial considerably differs from the 'real world' setting in the present study. The percentage of patients with elevated baseline LDH was 36% compared to 49% in our study. Other significant differences between the CheckMate 067 trial and our study included 41% vs. 49% patients ≥ 65 years, 59% vs. 87% stage M1c, 28% vs. 13% patients with only one lesion site, 4% vs. 29% brain metastasis. The circumstance of stable or even increasing LDH levels in
responders to combined immunotherapy raises the question whether the high frequency of immune-related adverse events could be responsible for this issue. Rising levels of LDH can be found for instance in patients developing autoimmune hepatitis or colitis. Afzal et al. reported on a case of a patient with uveal melanoma developing autoimmune hepatitis with concomitant continuously rising LDH while responding on ipilimumab plus nivolumab. Therefore, for patients receiving combined checkpoint inhibition with ipilimumab and nivolumab, LDH cannot be certainly considered as the main prognostic marker, at least in the setting of early biomarker changes during therapy. Additional markers for response and survival are required. Compared with the modest results for LDH in the present study, both baseline S100B > 0.3 μg/l as well as increases in S100B levels of more than 145% were significantly associated with poor OS in our data. Furthermore, the results were highly significant for S100B increases in patients with PD and decreases in patients with PR or CR, respectively.

We are aware of limitations of our study. The retrospective design makes it susceptible for a patient selection bias. However, we included all consecutive patients at our centre receiving pembrolizumab or combined nivolumab plus ipilimumab. Thereby, there was probably even less selection than in most clinical trials where patients with ECOG status > 1 or brain metastasis are either excluded or underrepresented. Another limitation of our study is the lack of information about the PD-L1 status in the tumour tissue which may be a prognostic and predictive marker for OS and response, especially in patients receiving the combination of nivolumab plus ipilimumab.

In conclusion, we postulate LDH and S100B to be useful and easily measurable markers at baseline and during treatment with pembrolizumab. They could be utilised to identify patients who might benefit from an earlier staging evaluation after 1.5–2 months compared to the usual 3 months. Those patients with increasing biomarker levels during the first weeks of immune checkpoint inhibition could therefore be forwarded earlier to a rescue therapy regimen. Although our data suggest a slight superiority of S100B compared to LDH, the definite assessment and comparison of the two biomarkers should be subject to larger prospective trials. Further prospective trials are required to confirm our results and to deepen the understanding of these biomarkers in guiding treatment decisions before and during the course of treatment.

ACKNOWLEDGEMENTS
We thank the whole team of the melanoma unit for their passionate patient care and support in data collection.

AUTHOR CONTRIBUTIONS
Conception and design: NBW and TKE. Collection and assembly of data: All authors. Data analysis and interpretation: NBW, AF, UL and TKE. Manuscript writing: All authors. Final approval of manuscript: All authors. Accountable for all aspects of the work: All authors.

ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/s41416-018-0167-x.

Ethics approval and consent to participate: This study has been performed in accordance with the Declaration of Helsinki and had been approved by the Ethics Committee of University Hospital Tuebingen (reference number 436/2017BO2). Written informed consent was obtained from all subjects.

Availability of data and material: The data that support the findings of this study are available from the corresponding author upon reasonable request.

S100B and LDH predict survival under anti-PD-1 blockade
NB Wagner et al.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests: Nikolaus Benjamin Wagner received travel support from Novartis and Forscherreports honoraria as a speaker from BMS, MSD, Roche and Novartis. She is advisory board member of Roche and Novartis and received travel support from Roche, Novartis and BMS. Ulrike Leiter declares no conflict of interest. Claus Garbe reports grants and personal fees from BMS during the conduct of the study; grants and personal fees from Roche, Novartis and personal fees from Amgen, MSD and Philogen outside the submitted work. Thomas Kurt Eigentler reports honoraria as a speaker from BMS. He is advisory board member of BMS, Roche and Novartis.

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
2. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).
3. Woloch, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
4. Zou, W., Wolchoł, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv34 (2016).
5. Eton, O. et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16, 1103–1111 (1998).
6. Weide, B. et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br. J. Cancer 107, 422–428 (2012).
7. Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).
8. Gershensonwald, J. E. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472–492 (2017).
9. Nosrati, A. et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br. J. Cancer 116, 1141–1147 (2017).
10. Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114, 256–261 (2016).
11. Gaynor, R., Irie, R., Morton, D. & Herschman, H. R. S100 protein is present in cutaneous malignant melanoma. Nature 286, 400–401 (1980).
12. Gaynor, R. et al. S100 protein in malignant melanoma: a marker for human malignant melanomas? Lancet 1, 869–871 (1981).
13. Nakajima, T. et al. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 50, 912–918 (1982).
14. Blessing, K., Sanders, D. S. & Grant, J. J. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 32, 139–146 (1998).
15. von Schloitz, E. et al. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 6, 133–137 (1996).
16. Schultz, E. S., Diepgen, T. L. & Von Den Driesch, P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br. J. Dermatol. 138, 426–430 (1998).
17. Hauschild, A. et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9, 155–161 (1999).
18. Jury, C. S., McAllister, E. J. & Mackie, R. M. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br. J. Dermatol. 143, 269–274 (2000).
19. Martenson, E. D. et al. Serum S-100 beta protein in patients with cutaneous melanoma: a meta-analysis. Int. J. Cancer 123, 2370–2376 (2008).
21. Eigentler, T. K., Muhlenbein, C., Follmann, M., Schadendorf, D. & Garbe, C. S3-Leitlinie diagnostik, therapie und nachsorge des melanoms—Update 2015/2016, Kurzversion 2.0. J. Dtsch. Dermatol. Ges. 15, e1–e41 (2017).
22. Felix, J. et al. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. Int Immunopharmacol. 40, 466–473 (2016).
23. Damuzzo, V. et al. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology 5, e1249559 (2016).
24. Gambichler T., et al. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. J. Eur. Acad. Dermatol. Venereol. 32, 972–977 (2017).
25. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
26. Hothorn, T. & Lausen, B. On the exact distribution of maximally selected rank statistics. Comput. Stat. Data Anal. 43, 121–137 (2003).
27. Manola, J., Atkins, M., Ibrahim, J. & Kirkwood, J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J. Clin. Oncol. 18, 3782–3793 (2000).
28. Deichmann, M. et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J. Clin. Oncol. 17, 1891–1896 (1999).
29. Weide, B. et al. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PLoS One 8, e81624 (2013).
30. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
31. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
32. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
33. Delyon, J. et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 24, 1697–1703 (2013).
34. Kelderman, S. et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunother. 63, 449–458 (2014).
35. Diem, S. et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur. J. Cancer 51, 2785–2791 (2015).
36. Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600–1609 (2016).
37. Valpione, S. et al. Personalised medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. Eur. J. Cancer 51, 2086–2094 (2015).
38. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).
39. Callahan M. K., et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J. Clin. Oncol. 2017, JCO2017722850 (2017).
40. Afzal, M. Z., Mabaera, R. & Shirai, K. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. J. Immunother. Cancer 6, 13 (2018).